ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANCA"

  • Abstract Number: 2731 • 2018 ACR/ARHP Annual Meeting

    Clinical Characteristics and Outcomes of ANCA-Vasculitides Associated Renal Disease in a Multi-Ethnic Population from a County Hospital

    Shilpa Arora1, Ambrish Athavale2 and Peter Hart2, 1Medicine, John H Jr Stroger Hospital of Cook County, Chicago, IL, 2John H Jr Stroger Hospital of Cook County, Chicago, IL

    Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal-limited vasculitis (RLV). We aimed to study the clinical features…
  • Abstract Number: 904 • 2018 ACR/ARHP Annual Meeting

    Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry

    John L. Niles1, Peter A. Merkel2, Lester Mertz3, Patricia B. Lehane4, Pooneh Pordeli5 and Félix Erblang6, 1Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Roche Products Ltd., Welwyn Garden City, United Kingdom, 5Hoffmann-La Roche Ltd., Mississauga, ON, Canada, 6Hoffmann-La Roche Ltd., Basel, Switzerland

    Background/Purpose: Potential therapy-related toxicities are important causes of morbidity in patients with the ANCA-associated vasculitides granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Long-term safety…
  • Abstract Number: 1765 • 2018 ACR/ARHP Annual Meeting

    Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis

    Yasuhiro Shimojima1, Dai Kishida2 and Yoshiki Sekijima2, 1Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, 2Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan

    Background/Purpose: Hypertrophic pachymeningitis (HP), which becomes the cause of chronic headache, seizure, and cranial neuropathy, is an inflammatory disorder demonstrating focal and diffuse thickening of…
  • Abstract Number: 2732 • 2018 ACR/ARHP Annual Meeting

    Peripheral Neuropathy Is More Common in Microscopic Polyangiitis Than in Granulomatosis with Polyangiitis: Data from a Single Tertiary Referral Center

    Mehmet Nedim Taş1, Mete Kara1, Sertaç Ketenci1, Mete Pekdiker2, Raika Durusoy3, Fikret Bademkıran4, Gokhan Keser5 and Kenan Aksu5, 1Rheumatology, Ege University Medical Faculty, izmir, Turkey, 2Adult Rheumatology, Ege University Medical Faculty, izmir, Turkey, 3Public Health, Ege University Medical Faculty, izmir, Turkey, 4Neurology, Ege University Medical Faculty, izmir, Turkey, 5Rheumatology, Ege University Medical Faculty, Izmir, Turkey

    Background/Purpose: Among many other organs and systems, ANCA-associated vasculitis (AAV) may also affect nervous system in up to more than half of patients, resulting in…
  • Abstract Number: 18L • 2017 ACR/ARHP Annual Meeting

    Rituximab As Re-Induction Therapy in Relapsing ANCA-Associated Vasculitis

    Rona Smith1, Rachel Jones2, Ulrich Specks3, Carol A McAlear4, Kim Mynard2, Simon Bond2, David Jayne5 and Peter A. Merkel6, 1Department of Medicine, University of Cambridge, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 2Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, 3Mayo Clinic College of Medicine, Rochester, MN, 4University of Pennsylvania, Philadelphia, PA, 5Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 6Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: RITAZAREM (ClinicalTrials.gov: NCT01697267) is an international, randomized, controlled trial comparing rituximab with azathioprine as maintenance therapy after induction of remission with rituximab and glucocorticoids…
  • Abstract Number: 1010 • 2017 ACR/ARHP Annual Meeting

    Identification of Circulating Biomarkers of Disease Activity and Organ Involvement in ANCA-Associated Vasculitis By Targeted Proteomics

    Jun Ishizaki1, Ayako Takemori2, Koichiro Suemori1, Takuya Matsumoto1, Yoko Akita1, Masaki Yasukawa1, Nobuaki Takemori2 and Hitoshi Hasegawa1, 1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, 2Division of Proteomics Research, Proteo-Science Center, Ehime University, Ehime, Japan

    Background/Purpose: Targeted proteomics, which involves quantitative analysis of targeted proteins using selected reaction monitoring (SRM) mass spectrometry, has emerged as a new methodology for discovery…
  • Abstract Number: 1770 • 2017 ACR/ARHP Annual Meeting

    ANCA-Associated Vasculitis (AAV) in Younger Vs Older Patients:  Comparison of Clinical, Serologic and Outcome Differences and Their Implications for Management

    Priya Chokshi1, Olufemi Aina2, Naveed Masani2, Melissa Fazzari3, Elise Belilos1, Kristina Belostocki1, Gary Rosenblum1, Tobin Abraham4, Daniil Shimonov4, Zinal Patel4 and Steven E. Carsons1, 1Rheumatology, NYU Winthrop Hospital, Mineola, NY, 2Nephrology, NYU Winthrop Hospital, Mineola, NY, 3Biostatistics, NYU Winthrop Hospital, Mineola, NY, 4Medicine, NYU Winthrop Hospital, Mineola, NY

    Background/Purpose: ANCA-associated vasculitis (AAV) is a cause of multi-organ disease in all ages, but peaks at ages 65-74. Limited data is available on the characteristics…
  • Abstract Number: 1013 • 2017 ACR/ARHP Annual Meeting

    HLA-Class II Associations with ANCA-Associated Vasculitis in the Japanese Population: Different Features from European Populations

    Aya Kawasaki1, Fumio Hirano2, Ken-ei Sada3, Shigeto Kobayashi4, Hidehiro Yamada5, Hiroshi Furukawa1, Kenji Nagasaka6, Takahiko Sugihara7, Kunihiro Yamagata8, Takayuki Sumida9, Shigeto Tohma10, Shoichi Ozaki5, Seiichi Matsuo11, Hiroshi Hashimoto12, Hirofumi Makino13, Yoshihiro Arimura14, Masayoshi Harigai15 and Naoyuki Tsuchiya1, 1Molecular and Genetic Epidemiology Laboratory, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, 2Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 3Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 4Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, 5Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 6Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, 7Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 8Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, 9Department of Internal Medicine, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, 10Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 11Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 12Juntendo University School of Medicine, Tokyo, Japan, 13Okayama University Hospital, Okayama, Japan, 14First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, 15Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: HLA-class II region harbors the strongest genetic factors for ANCA-associated vasculitis (AAV), and differences in the genetic background of HLA-class II may partly explain…
  • Abstract Number: 1771 • 2017 ACR/ARHP Annual Meeting

    Prevalence and Prognostic Relevance of Cardiovascular Involvement in ANCA-Associated Vasculitis: A Retrospective Cohort Study

    Qin Huang1, Hao Ren1, Yaping Zhan2, Shenyi Yu2 and Min Yang1, 1Department of Rheumatology, Nanfang Hospital,Southern Medical University, Guangzhou, China, 2Department of rheumatology, Nanfang Hospital,Southern Medical University, Guangzhou, China

    Background/Purpose: Cardiovascular involvement in ANCA-associated vasculitis (AAV) including microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA), has long been regarded…
  • Abstract Number: 1288 • 2017 ACR/ARHP Annual Meeting

    Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study

    Kimberly Morishita1, Audrea Chen2, Cherry Mammen1, Angelyne Rivera3 and David Cabral1, 1BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 2Medicine, University of British Columbia, Vancouver, BC, Canada, 3Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Renal disease is the most common manifestation of pediatric anti-neutrophil cycloplasmic antibody (ANCA) associated vasculitis (AAV). Renal disease course and early trajectories have not…
  • Abstract Number: 1772 • 2017 ACR/ARHP Annual Meeting

    Non-Protocolized Re-Biopsy in Patients with ANCA-Associated Glomerulonephritis: ¿Is It Necessary?

    Valeria Scaglioni1, Marina Scolnik2, Florencia Pierini2, Luis J. Catoggio3, Silvia Beatriz Christiansen4, Carlos Federico Varela5, Gustavo Greloni5, Guillermo Rosa-Diez5 and Enrique R Soriano6, 1Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, CABA, Argentina, 2Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, 3Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Pathology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Nephrology Service. Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, 6Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: Protocolized and non-protocolized repeat renal biopsies are rarely performed in ANCA glomerulonephritis. Their role in predicting long term renal outcomes and aiding in clinical…
  • Abstract Number: 1289 • 2017 ACR/ARHP Annual Meeting

    Assessing ACR/EULAR Provisional 2017 Classification Criteria for Granulomatosis with Polyangiitis (GPA) in a Cohort of 376 Children with Small to Medium Vessel Chronic Vasculitis – a Pediatric Vasculitis Initiative (PedVas) Study

    Angelyne Rivera1, Kimberly Morishita2, David Cabral2 and Raashid Luqmani3, 1Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 2BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 3Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

     Background/Purpose: Classification of chronic vasculitis to clinically or etiologically meaningful groups has been challenging.  In 2008, the 1990 ACR classification criteria for GPA was adapted…
  • Abstract Number: 1773 • 2017 ACR/ARHP Annual Meeting

    New Use for an Old Drug: Hydroxychloroquine for the Treatment of ANCA Associated Vasculitis

    Alina Casian1, Rachel Jones2, Ruzaika Cader3, Alan D. Salama4, Shirish Sangle5, David Jayne6 and David P. D'Cruz7, 1Lupus Unit, Guy's Hospital, London, United Kingdom, 2Nephrology, Addenbrooke's Hospital, Cambridge, United Kingdom, 3Nephrology, Norfolk and Norwich Hospitals, Norfolk, United Kingdom, 4Centre for Nephrology, University College London, London, United Kingdom, 5Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, 6Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 7Louise Coote Lupus Unit, Rheumatology and Lupus, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: To assess retrospectively the efficacy and safety of hydroxychloroquine in patients with ANCA associated vasculitis. There is an unmet need for a corticosteroid sparing, non-toxic…
  • Abstract Number: 1750 • 2017 ACR/ARHP Annual Meeting

    Risk of Cardiovascular and Thrombotic Disease Among Patients with Incident ANCA-Associated Vasculitis: A 20 Year Population Based Cohort Study

    Alvise Berti1,2, Eric L. Matteson3,4, Cynthia S. Crowson5,6, Ulrich Specks7 and Divi Cornec8,9, 1Department of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, 2Department of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milan, Italy, 3Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 4Department of Health Sciences Research, Division of Epidemiology, Rochester, MN, 5Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 6Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 7Mayo Clinic College of Medicine, Rochester, MN, 8Department of Rheumatology, Brest Teaching Hospital, Brest, France, 9Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN

    Background/Purpose: ANCA-associated vasculitides (AAV) are characterized by inflammation and necrosis of small-sized vessels. Because cardiovascular disease (CVD) is a leading contributor to morbidity and mortality,…
  • Abstract Number: 1776 • 2017 ACR/ARHP Annual Meeting

    Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan

    Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan

    Background/Purpose: The combination of immunosuppressants and glucocorticoid is recommended for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, adverse events of immunosuppressants sometimes…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology